erlofitinib

FDA Grants Accelerated Approval to Erdafitinib for Metastatic Urothelial Carcinoma Bookmark

Press release from the U.S. Food and Drug Administration (FDA) curated by Editor in Chief George Lundberg, MD, who notes: 

The FDA has granted accelerated approval for the drug erlofitinib in advanced urothelial malignancies that meet specific criteria.

Go to full article published by the FDA.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.